Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mito-MES for COVID-19 Postexposure Prophylaxis
NCT05886816Phase 2Completed
- Sponsor
- UT Southwestern Medical Center
- Start
- Mar 2024
- Primary completion
- Feb 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised trial of mitoquinone in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by UT Southwestern Medical Center. Primary endpoint: SARS-CoV-2 infection at 14 days. Started Mar 2024; status: completed.
02
Drugs
mitoquinone
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05886816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05886816.